Status:
COMPLETED
Regorafenib Post-marketing Surveillance
Lead Sponsor:
Bayer
Conditions:
Colorectal Neoplasms
Eligibility:
All Genders
Brief Summary
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer. The objective o...
Eligibility Criteria
Inclusion
- Patients
- who are determined to start Regorafenib/ STIVARGA treatment
Exclusion
- Patients who have previously received Regorafenib/ STIVARGA
Key Trial Info
Start Date :
April 22 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 14 2016
Estimated Enrollment :
1301 Patients enrolled
Trial Details
Trial ID
NCT01843400
Start Date
April 22 2013
End Date
November 14 2016
Last Update
August 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Japan